Meta‐analysis of clinical trials with competing time‐to‐event endpoints - Cnam - Conservatoire national des arts et métiers Access content directly
Journal Articles Biometrical Journal Year : 2020

Meta‐analysis of clinical trials with competing time‐to‐event endpoints

Abstract

Recommendations for the analysis of competing risks in the context of randomized clinical trials are well established. Meta-analysis of individual patient data (IPD) is the gold standard for synthesizing evidence for clinical interpretation based on multiple studies. Surprisingly, no formal guidelines have been yet proposed to conduct an IPD meta-analysis with competing risk endpoints. To fill this gap, this work details (i) how to handle the heterogeneity between trials via a stratified regression model for competing risks and (ii) that the usual metrics of inconsistency to assess heterogeneity can readily be employed. Our proposal is illustrated by the re-analysis of a recently published meta-analysis in nasopharyngeal carcinoma, aiming at quantifying the benefit of the addition of chemotherapy to radiotherapy on each competing endpoint.
No file

Dates and versions

hal-04046961 , version 1 (27-03-2023)

Licence

Copyright

Identifiers

Cite

Alessandra Meddis, Aurélien Latouche, Bingqing Zhou, Stefan Michiels, Jason Fine. Meta‐analysis of clinical trials with competing time‐to‐event endpoints. Biometrical Journal, 2020, 62 (3), pp.712-723. ⟨10.1002/bimj.201900103⟩. ⟨hal-04046961⟩
25 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More